Literature DB >> 2423966

RNA metabolism in nuclei: selective transport of kappa exons from myeloma nuclei and adenoviral transcripts from infected HeLa nuclei.

R Patterson, E Werner, J Fetherston.   

Abstract

Two independent systems and several analytical procedures have been used to establish that isolated mammalian nuclei selectively transport mature RNA polymerase I and II products. Murine myeloma nuclei retain physiologic restriction in our transport assay as assessed by the transport of the immunoglobulin kappa light chain mRNA and 18S and 28S rRNAs. Nearly 50% of the total kappa exons are transported as structurally intact mature mRNA molecules while less than 8% of either pulse-labeled or steady state kappa intron sequences are detected in the transported fraction. Ribosomal external transcribed spacer sequences also are absent in transported RNA. Release of cytoplasmic RNA from the outer nuclear membrane during the transport assay accounts for less than 10% of transported RNA. Nuclei isolated from adenovirus-infected HeLa cells at 20 hours post infection retain cellular actin mRNA and transport viral poly A+RNA. Ribosomal RNA is transported from infected nuclei although at a reduced rate compared to transport from mock-infected nuclei. Inhibition of transport of host mRNA is paralleled by the absence of pulse-labeled actin mRNA in the cytoplasm of infected cells. The implications of our transport data in relationship to intranuclear RNA trafficking are discussed.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2423966      PMCID: PMC339852          DOI: 10.1093/nar/14.10.4159

Source DB:  PubMed          Journal:  Nucleic Acids Res        ISSN: 0305-1048            Impact factor:   16.971


  25 in total

1.  Nuclear RNA precursors in the processing pathway to MOPC 21 kappa light chain messenger RNA.

Authors:  M Gilmore-Hebert; R Wall
Journal:  J Mol Biol       Date:  1979-12-25       Impact factor: 5.469

2.  Recombinant DNA clones constructed from immunoglobulin kappa light chain messenger RNA.

Authors:  R Wall; M Gilmore-Hebert; R Higuchi; M Komaromy; G Paddock; J Strommer; W Salser
Journal:  Nucleic Acids Res       Date:  1978-09       Impact factor: 16.971

3.  Nuclear restriction of nucleic acids in the presence of ATP.

Authors:  S E Stuart; F M Rottman; R J Patterson
Journal:  Biochem Biophys Res Commun       Date:  1975-01-20       Impact factor: 3.575

4.  Inhibition of HeLa cell protein synthesis during adenovirus infection. Restriction of cellular messenger RNA sequences to the nucleus.

Authors:  G A Beltz; S J Flint
Journal:  J Mol Biol       Date:  1979-06-25       Impact factor: 5.469

5.  Labeling deoxyribonucleic acid to high specific activity in vitro by nick translation with DNA polymerase I.

Authors:  P W Rigby; M Dieckmann; C Rhodes; P Berg
Journal:  J Mol Biol       Date:  1977-06-15       Impact factor: 5.469

6.  Ribonucleic acid isolated by cesium chloride centrifugation.

Authors:  V Glisin; R Crkvenjakov; C Byus
Journal:  Biochemistry       Date:  1974-06-04       Impact factor: 3.162

7.  Release of adenovirus messenger RNA from isolated nuclei.

Authors:  H J Raskas
Journal:  Nat New Biol       Date:  1971-09-29

8.  Hybridization of denatured RNA and small DNA fragments transferred to nitrocellulose.

Authors:  P S Thomas
Journal:  Proc Natl Acad Sci U S A       Date:  1980-09       Impact factor: 11.205

9.  Purification and cloning of a mouse ribosomal gene fragment in coliphage lambda.

Authors:  D C Tiemeier; S M Tilghman; P Leder
Journal:  Gene       Date:  1977       Impact factor: 3.688

10.  Transport of beta-globin mRNA from nuclei of murine Friend erythroleukemia cells. Reversible inhibition of transport by the oxidizing sulfhydryl reagent o-iodosobenzoate.

Authors:  I Kindås-Mügge; G Sauermann
Journal:  Eur J Biochem       Date:  1985-04-01
View more
  1 in total

1.  RNA metabolism in nuclei: adenovirus and heat shock alter intranuclear RNA compartmentalization.

Authors:  R M Denome; E A Werner; R J Patterson
Journal:  Nucleic Acids Res       Date:  1989-03-11       Impact factor: 16.971

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.